The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (UC) after checkpoint inhibitor therapy (CIT).
 
Gurjyot K. Doshi
Research Funding - Mirati Therapeutics (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Caris Life Sciences; Fujifilm; Genentech/Roche; HERON; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; US Oncology
 
Donald A. Richards
Consulting or Advisory Role - Boehringer Ingelheim; Insys Therapeutics; IntegraGen; Lilly; Merrimack; Pharmacyclics
Speakers' Bureau - Celgene
 
Daniel Chong
Research Funding - Mirati Therapeutics (Inst)
 
David R. Shaffer
No Relationships to Disclose
 
Luke T. Nordquist
No Relationships to Disclose
 
Joel Picus
Consulting or Advisory Role - Novo Nordisk; Sanofi
Research Funding - Agensys (Inst); BioClin Therapeutics (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Innocrin Pharma (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst); TRACON Pharma (Inst)
 
Delia Alvarez
Employment - Mirati Therapeutics; TRACON Pharma
Stock and Other Ownership Interests - Mirati Therapeutics; TRACON Pharma
 
Hirak Der-Torossian
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
James Christensen
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Bluebird Bio; Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Multiple patents in last 2 years while employed at Mirati Therapeutics covering discovery of KRAS, LSD1, and EZH2 inhibitors. (Inst)
 
Jeffrey Thomas Yorio
Research Funding - Mirati Therapeutics (Inst)